Common Contracts
2 similar Supplemental Indenture contracts by Valeant Pharmaceuticals International, Inc.
EIGHTH SUPPLEMENTAL INDENTURESupplemental Indenture • November 1st, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
EIGHTH SUPPLEMENTAL INDENTURE, dated as of September 9, 2013 (the “Eighth Supplemental Indenture”),by and among Valeant Pharmaceuticals Australasia Pty Limited (ACN 001 083 352), DermaTech Pty Limited (ACN 003 982 161), Private Formula International Holdings Pty Ltd (ACN 095 450 918), Private Formula International Pty Ltd (ACN 095 451 442), Ganehill Pty Ltd (ACN 065 261 538) (collectively, the “New Guarantors”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
EIGHTH SUPPLEMENTAL INDENTURESupplemental Indenture • November 1st, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
EIGHTH SUPPLEMENTAL INDENTURE, dated as of September 9, 2013 (the “Eighth Supplemental Indenture”), by and among Valeant Pharmaceuticals Australasia Pty Limited (ACN 001 083 352), DermaTech Pty Limited (ACN 003 982 161), Private Formula International Holdings Pty Ltd (ACN 095 450 918), Private Formula International Pty Ltd (ACN 095 451 442), Ganehill Pty Ltd (ACN 065 261 538) (collectively, the “New Guarantors”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
